SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a major focus of community debate, with bulls citing potential ecosystem utility and network development as long-term catalysts, while vocal critics dismiss the token as a stagnant asset. Market participants are actively comparing SHIB's performance against newer meme coins and discussing the impact of ongoing token burn efforts on its long-term viability.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing extreme volatility and a sharp downward slide that has many retail investors questioning its long-term viability as the token reaches multi-year lows. Community sentiment is deeply divided between those calling for a total exit due to perceived tokenomic issues and those treating the current price as a generational accumulation opportunity based on the project's real-world institutional adoption.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently facing intense polarization, with bullish investors citing long-term ecosystem potential and recent developments, while bearish voices point to underperformance compared to newer project iterations and broader market stagnation. The community remains deeply divided, characterized by aggressive debates over tokenomics, the impact of recent leadership announcements, and the ongoing struggle to break out of its current technical trading range.

Anthropic

Anthropic is currently in the spotlight due to high-stakes IPO preparations and a series of strategic multi-billion dollar compute and infrastructure partnerships with major tech players. The community is actively debating the company's competitive standing against OpenAI, concerns regarding AI governance and export controls, and the broader implications of its rapid enterprise adoption.

OpenAI

OpenAI is currently trending as investors focus on its path toward a highly anticipated IPO and the broader implications of its massive capital expenditure requirements. The community is actively debating the company's competitive standing against rivals like Anthropic, the potential for government equity stakes, and the sustainability of its infrastructure spending.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is experiencing significant volatility and community debate following the departure of a major subnet developer, sparking concerns over the project's decentralization. Despite this, many investors remain bullish on TAO's long-term utility in the decentralized AI sector, viewing the price dip as a strategic opportunity to accumulate.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is seeing heightened market volatility and active community debate as investors react to the FDA accepting the resubmission of its RP1 Biologics License Application for advanced melanoma, setting an August 2 regulatory decision date. The stock remains a focal point for high-risk trading and options activity, with significant discussion centered on the possibility of a third complete response letter versus a potential regulatory turnaround under a shifting FDA environment.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors monitor ongoing institutional inflows and volatility across the broader crypto landscape. The community is actively debating the impact of upcoming legislative updates and the correlation between Bitcoin's price movements and various macroeconomic factors.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as supporters highlight its status as a Bitcoin-native asset and its integration with the Runes protocol, fueling high-conviction community discussions about its long-term potential. While the project faces skepticism regarding its price performance and accusations of influencer-led manipulation, the dedicated base remains focused on its role within the Bitcoin ecosystem.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending as investors digest the company's major all-stock merger with Coterra Energy, which aims to create a dominant U.S. shale producer with significant cost synergies and a boosted shareholder return framework. Community sentiment is largely focused on the potential for long-term cash flow growth and improved operational efficiency, with many traders actively monitoring aggressive call option accumulation ahead of upcoming earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI, Clinical Data, and Regulatory Catalysts have Wall Street Watching These Biotechs

Three emerging biotechnology companies, Can-Fite BioPharma (NYSEAMERICAN:CANF), NeOnc Technologies (NASDAQ:NTHI), and PMGC Holdings (NASDAQ:ELAB) through its NorthStrive Biosciences subsidiary, are pursuing a distinct therapeutic strategy, the common theme is execution. Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the second half of 2026.

Why Is CANF Stock Surging Today?

Equity

Can-Fite said Namodenoson met the Phase IIa study's main safety goal and demonstrated durable overall survival.

CANF Stock Pulls Back After Patent-Fueled Surge – Retail Calls It Consolidation Ahead Of Next Leg Up

Can-Fite BioPharma announced it has received a patent in Japan for its obesity therapy.

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.

Power, Compute and Breakthrough Science

Today’s headlines underscore a decisive shift toward owning the infrastructure, power, and materials that will underpin the next phase of the AI economy, including $KBLB, $VCIG, $CANF, $ASNS, $BW, and $APLD

Why Did CANF Stock Soar 25% Today?

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

This Microcap Just Locked Up New IP in a Massive Pharma Market

In biotechnology, intellectual property wins often act as quiet but powerful catalysts, particularly when they extend a platform into new therapeutic categories or unlock access to large international markets. As competition intensifies and pipelines mature, patent protection remains a key driver of long-term value, especially for companies advancing novel mechanisms with broad clinical applicability.Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF) are surging Friday after the company announced it was granted a new patent in Brazil covering the treatment of sexual dysfunction. The ...

Can-Fite BioPharma Shares Surged 50% In Pre-Market On Brazilian Patent Win

The company said it was granted a patent covering the use of its A3 adenosine receptor agonists for the treatment of sexual dysfunction in Brazil.

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Can-Fite Biopharma Ltd - ADR

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$3.19
Prev Close	$3.23
Open	$3.20
Dividend Yield	0.00%
50-Day Moving Average	$3.24
Beta	0.64
Avg. Volume	1.26M
PE Ratio	-0.26

52-Week High	$20.00
52-Week Low	$2.56
Market Capitalization	$6.83M
EPS (Annual)	-$12.03
Price to Book	0.75
Revenue Per Employee	$81,642.60

Feed

News

Sentiment

Fundamentals

Info

CANFCan-Fite BioPharma Ltd.

Latest CANF News